P Gp Or Bcrp Substrates + Capmatinib Interaction
Moderateinteraction on record
Description
Coadministration increased P-gp substrate exposure, which may increase adverse reactions. Decrease substrate dosage if coadministration unavoidable and minimal concentration changes may lead to serious reactions.
Mechanism
TABRECTA inhibits P-gp, increasing substrate exposure
Source: NLP:capmatinib